Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics reported that their dual-acting GLP-1/GIP receptor agonist induced nearly 18% mean weight loss at 48 weeks in obese patients during a Phase III trial conducted in China. The treatment demonstrated sustained efficacy without plateauing, with most adverse events being mild to moderate gastrointestinal symptoms. Hengrui plans to file for approval in China, and Kailera will pursue global studies evaluating higher doses and longer treatment durations. This promising result bolsters the competitive obesity drug market.